### This week in therapeutics

<table>
<thead>
<tr>
<th>Indication</th>
<th>Target/marker/pathway</th>
<th>Summary</th>
<th>Licensing status</th>
<th>Publication and contact information</th>
</tr>
</thead>
</table>
| Cancer      | Nicotinamide adenine dinucleotide (NAD$^+$); unconventional prefoldin RPB5 interactor (URI1; URI) | Studies in mice and human samples suggest increasing NAD$^+$ could help treat or prevent hepatocellular carcinoma (HCC). In mice, hepatocyte-specific expression of the NAD$^+$ synthesis inhibitor human URI1 induced spontaneous HCC tumors. In the mouse model of HCC, dietary supplementation with nicotinamide riboside—which increases NAD$^+$ synthesis—decreased tumor formation compared with a normal diet. In human HCC tumor samples, URI1 expression was higher than that in peritumoral or normal tissues, and high URI1 expression correlated with poor prognosis. Ongoing studies include testing nicotinamide riboside in xenograft models and in combination with chemotherapeutics. | Patent application filed; available for licensing | Tummala, K.S. et al. Cancer Cell; published online Nov. 20, 2014; doi:10.1016/j.ccell.2014.10.002  
Contact: Nabil Djouder, Spanish National Cancer Research Centre (CNIO), Madrid, Spain  
e-mail: ndjouder@cnio.es |

SciBX 7(47); doi:10.1038/scibx.2014.1371  
Published online Dec. 11, 2014